Abstract
Alpha-1 blockers, often used to treat benign prostate hyperplasia (BPH), have been hypothesized to prevent COVID-19 complications by minimising cytokine storms release. We conducted a prevalent-user active-comparator cohort study to assess association between alpha-1 blocker use and risks of three COVID-19 outcomes: diagnosis, hospitalization, and hospitalization requiring intensive services. Our study included 2.6 and 0.46 million users of alpha-1 blockers and of alternative BPH therapy during the period between November 2019 and January 2020, found in electronic health records from Spain (SIDIAP) and the United States (Department of Veterans Affairs, Columbia University Irving Medical Center, IQVIA OpenClaims, Optum DOD, Optum EHR). We estimated hazard ratios using state-of-the-art techniques to minimize potential confounding, including large-scale propensity score matching/stratification and negative control calibration. We found no differential risk for any of COVID-19 outcome, pointing to the need for further research on potential COVID-19 therapies.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work. DPA reports grants and other from AMGEN, grants, non-financial support and other from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work; and HTA Funding Committee membership. Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA's department and open for external participants. CR and KK are employees of IQVIA. "MAS receives grants from the National Institutes of Health and IQVIA and contracts from the US Food & Drug Administration, US Department of Veterans Affairs, Janssen Research & Development and Private Health Management all outside the scope of this work. CB, AS, MMC, JW, AGS, MJS, JR, and PBR are employees of Janssen Research & Development. SLD, KL and MEM are employees of the US Department of Veterans Affairs (VA) and report funding from the VA Informatics and Computing Infrastructure (VA HSR RES 13-457). SLD reports research grants from the following for-profit organizations: AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Pharmaceuticals LP, Biodesix, Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Genentech Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Innocrin Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Kantar Health, Myriad Genetic Laboratories, Inc., Novartis International AG, and Parexel International Corporation through the University of Utah or Western Institute for Veteran Research outside the submitted work. DRM has received support from the National Institute for Health Research, Scottish Chief Scientist Office and Tenovus Scotland unrelated to this work. NP received grants from the Australian National Health and Medical Research Council GNT1157506. PRR received support for this project from the European Health Data and Evidence.
Funding Statement
AN receives contract support from the U.S. Food and Drug Administration (HHS-FDA 75F40120D00039). JX receives scholarship from the Clarendon Fund and Jardine Foundation. KK and CR are employees of IQVIA. TDS and DPA received support for this project from the European Health Data and Evidence Network (EHDEN) project. EHDEN received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Unions Horizon 2020 research and innovation programme and EFPIA. This project is funded by the Health Department from the Generalitat de Catalunya with a grant for research projects on SARS-CoV-2 and COVID-19 disease organized by the Direccio General de Recerca i Innovacio en Salut. CB, AS, MMC, JW, AGS, MJS, JR, and PBR are employees of Janssen Research & Development. SLD, KL and MEM are employees of the US Department of Veterans Affairs (VA) and report funding from the VA Informatics and Computing Infrastructure (VA HSR RES 13-457). SLD reports research grants from the following for-profit organizations: AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Pharmaceuticals LP, Biodesix, Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Genentech Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Innocrin Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Kantar Health, Myriad Genetic Laboratories, Inc., Novartis International AG, and Parexel International Corporation through the University of Utah or Western Institute for Veteran Research outside the submitted work. DRM is funded by a Wellcome Trust Clinical Research Career Development Fellowship (Grant 214588/Z/18/Z) and has received support from the National Institute for Health Research, Scottish Chief Scientist Office and Tenovus Scotland unrelated to this work. NP received grants from the Australian National Health and Medical Research Council GNT1157506. PRR received support for this project from the European Health Data and Evidence Network(EHDEN) project. EHDEN has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 806968. The JU receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA. GH receives a grant for this work from the US National Institutes of Health (R01 LM006910). DPA receives support from NIHR Senior Research Fellowship (SRF-2018-11-ST2-004), and from the Bill and Melinda Gates Foundation (INV016201). The University of Oxford also received partial support from the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. This work has received support from the European Health Data and Evidence Network(EHDEN) project. EHDEN has received funding from the Innovative Medicines Initiative 2Joint Undertaking (JU) under grant agreement No. 806968. The JU receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA. MAS receives grants from the National Institutes of Health and IQVIA and contracts from the US Food & Drug Administration, US Department of Veterans Affairs, Janssen Research & Development and Private Health Management all outside the scope of this work. The views and opinions expressed are those of the authors and do not necessarily reflect those of the NIHR Academy programme, NIHR, Bill & Melinda Gates Foundation, US Department of Veterans Affairs, United States Government, NHS, National Institutes of Health or the Department of Health, England.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data partners received IRB approval or waiver in accordance with their institutional governance guidelines. Use of the SIDIAP data source was approved by the Clinical Research Ethics Committee of IDIAPJGol (project code: 20/070-PCV). Use of the VA-OMOP data source was reviewed by the Department of Veterans Affairs Central Institutional Review Board (IRB) and was determined to meet the criteria for exemption under Exemption Category 4(3) and approved the request for Waiver of HIPAA Authorization. Use of the CUIMC data source was approved by the Columbia University IRB as an OHDSI network study (IRB# AAAO7805). IQVIA Open Claims, Optum EHR, and Optum DOD are commercially available, syndicated data assets that are licensed by contributing authors for observational research. These assets are de-identified commercially available data products that could be purchased and licensed by any researcher. The collection and de-identification of these data assets is a process that is commercial intellectual property and not privileged to the data licensees and the co-authors on this study. Licensees of these data have signed Data Use Agreements with the data vendors which detail the usage protocols for running retrospective research on these databases. All analyses performed in this study were in accordance with Data Use Agreement terms as specified by the data owners. As these data are deemed commercial assets, there is no Institutional Review Board applicable to the usage and dissemination of these result sets or required registration of the protocol with additional ethics oversight. Compliance with Data Use Agreement terms, which stipulate how these data can be used and for what purpose, is sufficient for the licensing commercial entities. Further inquiry related to the governance oversight of these assets can be made with the respective commercial entities: IQVIA (iqvia.com) and Optum (optum.com). At no point in the course of this study were the authors of this study exposed to identified patient-level data. All result sets represent aggregate, de-identified data that are represented at a minimum cell size of >5 to reduce potential for re-identification. Furthermore, the New England Institutional Review Board of Janssen Research & Development (Raritan, NJ) has determined that studies conducted on licensed copies of Optum databases are exempt from study-specific IRB review, as these studies do not qualify as human subjects research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
"We obtained routinely-collected electronic health records (EHRs) and claims data from Spain and the United States (US). All data sources had been previously mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDMv5) (Hripcsak et al. 2015). This enabled distributed network analyses without sharing patient-level data, whilst ensuring data provenance, by applying common analytical programmes across data partner centers. Each site obtained institutional review board approval, or confirmed the study to be exempt or deemed not human subjects research."
